Our group has developed the therapeutic vaccine CSF-470, an allogeneic mixture of four-lethally irradiated cutaneous melanoma (CM) cell lines co-adjuvated with bacillus Calmette–Guerin (BCG) and recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF), for the adjuvant treatment of stages IIB–IIC–III CM patients. Here, CSF2 is linked to cutaneous mastocytosis.